the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid.
.
.
.
| featured:
.
.
fremanezumab has completed phase iii trials and is under review by the fda to prevent migraine and
.
. the study used data of 1,082 ct scans of stroke patients across 70 hospitals in britain.
.
.
.